Evidence map›Paper›PMID 39296283›Full record

ArticleFrontiers in molecular neuroscience2024

A novel super-resolution microscopy platform for cutaneous alpha-synuclein detection in Parkinson's disease.

Ofir Sade, Daphna Fischel, Noa Barak-Broner, Shir Halevi, Irit Gottfried, Dana Bar-On, Stefan Sachs, Anat Mirelman, Avner Thaler, Aviv Gour and 13 more

Abstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ofir SadeSchool of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.
Daphna FischelSchool of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.
Noa Barak-BronerSchool of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.
Shir HaleviSchool of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.
Irit GottfriedSchool of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.
Dana Bar-OnSchool of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.
Stefan SachsDepartment of Biotechnology and Biophysics, Biocenter, University of Würzburg, Würzburg, Germany.
Anat MirelmanSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Avner ThalerMovement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Aviv GourFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Meir KestenbaumFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Mali Gana WeiszMovement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Saar AnisFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Claudio SotoMitchell Center for Alzheimer's Disease and Related Brain Disorders, University of Texas Medical School, Houston, TX, United States.
Melanie Shanie RoitmanDepartment of Neurology, Movement Disorders Institute, Chaim Sheba Medical Center, Ramat Gan, Israel.
Shimon ShaharDepartment of Statistics, Exact Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.
Kathrin DopplerDepartment of Neurology, University Hospital Würzburg, Würzburg, Germany.
Markus SauerDepartment of Biotechnology and Biophysics, Biocenter, University of Würzburg, Würzburg, Germany.
Nir GiladiSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Nirit LevSagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Roy N AlcalayMovement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Sharon Hassin-BaerFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Uri AsherySchool of Neurobiology, Biochemistry, Biophysics, Life Sciences Faculty, Tel Aviv University, Tel Aviv, Israel.

Funding

Production and Distribution of well-characterized polymorphic variants of alpha-synuclein aggregatesU24AG079685 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CLAUDIO SOTO · 2022 to 2026
$3.8M
NIA NIH HHS U24 AG079685
6 · The paper itself

Abstract

Alpha-synuclein (aSyn) aggregates in the central nervous system are the main pathological hallmark of Parkinson's disease (PD). ASyn aggregates have also been detected in many peripheral tissues, including the skin, thus providing a novel and accessible target tissue for the detection of PD pathology. Still, a well-established validated quantitative biomarker for early diagnosis of PD that also allows for tracking of disease progression remains lacking. The main goal of this research was to characterize aSyn aggregates in skin biopsies as a comparative and quantitative measure for PD pathology. Using direct stochastic optical reconstruction microscopy (

Indexed as

alpha-synuclein aggregatesbiomarkerdensity-based spatial clustering of applications with noise (DBSCAN)direct stochastic optical reconstruction microscopy (dSTORM)early diagnosisfast optimized cluster algorithm for localizations (FOCAL)Parkinson’s diseasesuper-resolution microscopy

Identifiers

PMID39296283
PMCPMC11409901

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.